title: Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography.
abstract: OBJECTIVE
  Recent in vivo imaging studies indicate a dysregulated presynaptic function of the striatal dopaminergic system in patients with schizophrenia. To further explore the basis of this phenomenon, the authors studied brain dopamine transporter binding in vivo in patients with first-episode, never-medicated schizophrenia.
  
  
  METHODS
  Nine patients with schizophrenia and nine healthy matched comparison subjects were recruited. Striatal dopamine transporter binding was measured with positron emission tomography and a specific dopamine transporter ligand, [(18)F]CFT, a radiolabeled form of 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane.
  
  
  RESULTS
  Average caudate and putamen dopamine transporter binding potentials were almost identical in the patients and comparison subjects, but the patients lacked the right-left asymmetry of the caudate dopamine transporter binding seen in the comparison group.
  
  
  CONCLUSIONS
  Average striatal dopamine transporter density is unaltered in neuroleptic-naive patients with schizophrenia. However, patients lack asymmetry in caudate dopamine transporter binding, which conforms with disrupted brain lateralization in this disorder.
authors.affiliation: Department of Psychiatry, University of Turku, Finland.
authors.forename: A
authors.initials: A
authors.lastname: Laakso
authors.forename: H
authors.initials: H
authors.lastname: Vilkman
authors.forename: B
authors.initials: B
authors.lastname: Alakare
authors.forename: M
authors.initials: M
authors.lastname: Haaparanta
authors.forename: J
authors.initials: J
authors.lastname: Bergman
authors.forename: O
authors.initials: O
authors.lastname: Solin
authors.forename: J
authors.initials: J
authors.lastname: Peurasaari
authors.forename: V
authors.initials: V
authors.lastname: Räkköläinen
authors.forename: E
authors.initials: E
authors.lastname: Syvälahti
authors.forename: J
authors.initials: J
authors.lastname: Hietala
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000503:physiopathology; D002352:Carrier Proteins / Q000737:chemistry / Q000378:metabolism*; D002421:Caudate Nucleus / Q000737:chemistry / Q000378:metabolism; D003042:Cocaine / Q000031:analogs & derivatives; D003342:Corpus Striatum / Q000737:chemistry*; D004298:Dopamine / Q000737:chemistry / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000503:physiopathology; D014055:Tomography, Emission-Computed
chemical_list: D014150:Antipsychotic Agents; D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C021279:(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester; D003042:Cocaine; D004298:Dopamine